IBIO iBio Inc
Price (delayed)
$4.12
Market cap
$40.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.67
Enterprise value
$38.2M
iBio is a global leader in plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and
Highlights
iBio's gross profit has surged by 114% QoQ
iBio's revenue has surged by 114% QoQ
IBIO's debt has plunged by 72% YoY but it is up by 7% from the previous quarter
The company's equity has surged by 51% YoY but it fell by 22% QoQ
IBIO's quick ratio has plunged by 53% from the previous quarter
Key stats
What are the main financial stats of IBIO
Market
Valuations
Earnings
Shares outstanding
9.87M
Market cap
$40.68M
Enterprise value
$38.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.71
Price to sales (P/S)
100.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
101.86
Revenue
$375,000
Gross profit
$375,000
Operating income
-$15.56M
Net income
-$19.3M
EBIT
-$19.08M
EBITDA
-$17.91M
Free cash flow
-$15.24M
Per share
Balance sheet
Liquidity
EPS
-$0.67
EPS diluted
-$0.67
Free cash flow per share
-$1.67
Book value per share
$1.52
Revenue per share
$0.04
TBVPS
$1.71
Total assets
$21.7M
Total liabilities
$7.8M
Debt
$4.75M
Equity
$13.9M
Working capital
$3.58M
Debt to equity
0.34
Current ratio
1.76
Quick ratio
1.54
Net debt/EBITDA
0.14
Margins
Efficiency
Dividend
EBITDA margin
-4,774.7%
Gross margin
100%
Net margin
-5,147.5%
Operating margin
-4,149.3%
Return on assets
-61.7%
Return on equity
-99.2%
Return on invested capital
-123%
Return on capital employed
-112.3%
Return on sales
-5,087.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IBIO stock price
How has the iBio stock price performed over time
Intraday
5.37%
1 week
-4.41%
1 month
-29.33%
1 year
44.06%
YTD
68.16%
QTD
2.49%
Financial performance
How have iBio's revenue and profit performed over time
Revenue
$375,000
Gross profit
$375,000
Operating income
-$15.56M
Net income
-$19.3M
Gross margin
100%
Net margin
-5,147.5%
iBio's gross profit has surged by 114% QoQ
iBio's revenue has surged by 114% QoQ
IBIO's net margin has soared by 91% YoY and by 61% from the previous quarter
The company's operating margin has surged by 90% YoY and by 54% QoQ
Growth
What is iBio's growth rate over time
Valuation
What is iBio stock price valuation
P/E
N/A
P/B
2.71
P/S
100.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
101.86
The EPS has soared by 96% YoY and by 85% from the previous quarter
IBIO's price to book (P/B) is 157% higher than its last 4 quarters average of 1.0 and 71% higher than its 5-year quarterly average of 1.5
The company's equity has surged by 51% YoY but it fell by 22% QoQ
iBio's revenue has surged by 114% QoQ
IBIO's price to sales (P/S) is 25% less than its last 4 quarters average of 126.7 but 2.9% more than its 5-year quarterly average of 92.5
Efficiency
How efficient is iBio business performance
The ROS has soared by 91% YoY and by 61% from the previous quarter
iBio's return on equity has increased by 50% YoY and by 22% QoQ
iBio's return on assets has increased by 11% YoY and by 8% QoQ
The ROIC has contracted by 5% YoY
Dividends
What is IBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IBIO.
Financial health
How did iBio financials performed over time
iBio's total assets is 178% more than its total liabilities
IBIO's current ratio has surged by 93% year-on-year but it is down by 48% since the previous quarter
The company's total liabilities has shrunk by 69% YoY but it rose by 15% QoQ
IBIO's debt is 66% less than its equity
The company's debt to equity has shrunk by 82% YoY but it rose by 36% QoQ
IBIO's debt has plunged by 72% YoY but it is up by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.